PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
Stefano Luminari,
Tae Min Kim,
Ashish Risal,
Manjusha Namuduri,
Jingxian Cai,
Bertha Fearon-Chalet,
Min Zhu,
Sushmita Mukherjee,
Jurriaan Brouwer-Visser,
Aafia Chaudhry,
Hesham Mohamed,
Srikanth Ambati,
Umberto Vitolo
Affiliations
Stefano Luminari
1 Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Tae Min Kim
2 Seoul National University Hospital, Seoul, Korea, Rep. of South
Ashish Risal
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Manjusha Namuduri
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Jingxian Cai
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Bertha Fearon-Chalet
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Min Zhu
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Sushmita Mukherjee
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Jurriaan Brouwer-Visser
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Aafia Chaudhry
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Hesham Mohamed
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Srikanth Ambati
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Umberto Vitolo
4 Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy
